[
  {
    "ts": null,
    "headline": "Why AbbVie (ABBV) Dipped More Than Broader Market Today",
    "summary": "In the latest trading session, AbbVie (ABBV) closed at $213.59, marking a -1.42% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=5d1516288f15659ee2705420e6612838834ff66c78b88312fe7c214b0f1503d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741729516,
      "headline": "Why AbbVie (ABBV) Dipped More Than Broader Market Today",
      "id": 133184491,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "In the latest trading session, AbbVie (ABBV) closed at $213.59, marking a -1.42% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=5d1516288f15659ee2705420e6612838834ff66c78b88312fe7c214b0f1503d6"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (NYSE:ABBV) Urges Shareholders To Reject Proposals On Voting Rules And Human Rights Due Diligence",
    "summary": "AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of its May 2025 meeting, fostering investor attention. Despite reporting a Q4 net loss, the company's stock surged by 23% in the last quarter, countering market volatility driven by tariff announcements from the Trump administration, which left major indices like the Dow and S&P 500 in decline. AbbVie's recent product approvals, such as the availability of SKYRIZI in...",
    "url": "https://finnhub.io/api/news?id=a20bb3a84138987814c0aa21fd052bbf49d5f30c364fab25d8507d855bc7d61b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741716797,
      "headline": "AbbVie (NYSE:ABBV) Urges Shareholders To Reject Proposals On Voting Rules And Human Rights Due Diligence",
      "id": 133184492,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of its May 2025 meeting, fostering investor attention. Despite reporting a Q4 net loss, the company's stock surged by 23% in the last quarter, countering market volatility driven by tariff announcements from the Trump administration, which left major indices like the Dow and S&P 500 in decline. AbbVie's recent product approvals, such as the availability of SKYRIZI in...",
      "url": "https://finnhub.io/api/news?id=a20bb3a84138987814c0aa21fd052bbf49d5f30c364fab25d8507d855bc7d61b"
    }
  },
  {
    "ts": null,
    "headline": "These 10 stocks beating the market’s recent Trump slump have this in common",
    "summary": "These 10 stocks beating the market’s recent Trump slump have this in common",
    "url": "https://finnhub.io/api/news?id=e8383f6a57268bab0c9cf132cc1de00ab367c29c1676d860b3901c1a8d646442",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741700400,
      "headline": "These 10 stocks beating the market’s recent Trump slump have this in common",
      "id": 133136678,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "These 10 stocks beating the market’s recent Trump slump have this in common",
      "url": "https://finnhub.io/api/news?id=e8383f6a57268bab0c9cf132cc1de00ab367c29c1676d860b3901c1a8d646442"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Leerink Partners Global Healthcare Conference (Transcript)",
    "summary": "AbbVie Inc. (NYSE:ABBV) Leerink Partners Global Healthcare Conference March 11, 2025 8:40 AM ETCompany ParticipantsJeff Stewart - Executive Vice President,...",
    "url": "https://finnhub.io/api/news?id=48b14131cfdbdcde9593f86873e58bbb1b78f3c6ca3f22a78541185c2c724dca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741698846,
      "headline": "AbbVie Inc. (ABBV) Leerink Partners Global Healthcare Conference (Transcript)",
      "id": 133136075,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. (NYSE:ABBV) Leerink Partners Global Healthcare Conference March 11, 2025 8:40 AM ETCompany ParticipantsJeff Stewart - Executive Vice President,...",
      "url": "https://finnhub.io/api/news?id=48b14131cfdbdcde9593f86873e58bbb1b78f3c6ca3f22a78541185c2c724dca"
    }
  },
  {
    "ts": null,
    "headline": "BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund",
    "summary": "BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=0a90bbc72c21544b52437a24252fdcd27158f61d0b5128e17ea6b2ed0058f641",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741698125,
      "headline": "BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund",
      "id": 133136036,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148098716/image_2148098716.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=0a90bbc72c21544b52437a24252fdcd27158f61d0b5128e17ea6b2ed0058f641"
    }
  },
  {
    "ts": null,
    "headline": "Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks",
    "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN).",
    "url": "https://finnhub.io/api/news?id=9fe4a725567f0ded1bfde5503ad24daef9853559a131d4fedf9568a7ea220327",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741683790,
      "headline": "Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks",
      "id": 133184494,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN).",
      "url": "https://finnhub.io/api/news?id=9fe4a725567f0ded1bfde5503ad24daef9853559a131d4fedf9568a7ea220327"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV): A Magnificent Dividend Growth Stock to Invest In",
    "summary": "We recently published a list of 10 Magnificent Dividend Growth Stocks to Invest In. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other magnificent dividend growth stocks to invest in. Dividend stocks remain a popular choice among investors due to their ability to generate steady income. […]",
    "url": "https://finnhub.io/api/news?id=19a7f8c82a160abd476b80da26c276b953fb359879ba4bdfa0320639aa578957",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741682258,
      "headline": "AbbVie Inc. (ABBV): A Magnificent Dividend Growth Stock to Invest In",
      "id": 133184495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Magnificent Dividend Growth Stocks to Invest In. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other magnificent dividend growth stocks to invest in. Dividend stocks remain a popular choice among investors due to their ability to generate steady income. […]",
      "url": "https://finnhub.io/api/news?id=19a7f8c82a160abd476b80da26c276b953fb359879ba4bdfa0320639aa578957"
    }
  }
]